Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate

Most gastrointestinal stromal tumors (GISTs) are caused by activating mutations of the KIT receptor tyrosine kinase. The small molecule inhibitor imatinib mesylate was initially developed to target the ABL1 kinase, which is constitutively activated through chromosomal translocation in BCR-ABL1-posit...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Rausch, Jessica L., Boichuk, Sergei, Ali, Areej A., Patil, Sneha S., Lee, Donna M., Brown, Matthew F., Makielski, Kathleen R., Liu, Ying, Taguchi, Takahiro, Kuan, Shih-Fan, Duensing, Anette
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5354847/
https://ncbi.nlm.nih.gov/pubmed/27965460
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13882
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars